Assessment of the performance of the IHS4-55 using data from a phase 2 study of bimekizumab in patients with hidradenitis suppurativa

被引：0
|
作者：
Tzellos, Thrasyvoulos [1 ,2 ]
Kyrgidis, Athanassios [1 ,3 ]
Alavi, Afsaneh [1 ,4 ]
van Straalen, Kelsey R. [1 ,5 ]
Pansar, Ingrid [6 ]
Davis, Leah [7 ]
Zouboulis, Christos C. [1 ,8 ,9 ,10 ,11 ,12 ]
机构：
[1] European Hidradenitis Suppurat Fdn eV, Dessau, Germany
[2] Nordland Hosp Trust, Dept Dermatol, Bodo, Norway
[3] Aristotle Univ Thessaloniki, Papanikolaou Gen Hosp Thessaloniki, Dept Maxillofacial Surg, Thessaloniki, Greece
[4] Mayo Clin, Dept Dermatol, Rochester, MN USA
[5] Univ Michigan, Dept Dermatol, Ann Arbor, MI USA
[6] UCB Pharma, Brussels, Belgium
[7] UCB Pharma, Morrisville, NY USA
[8] Brandenburg Med Sch Theodor Fontane, Dessau, Germany
[9] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Dermatol, Dessau, Germany
[10] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Venereol, Dessau, Germany
[11] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Allergol, Dessau, Germany
[12] Staedt Klinikum Dessau, Fac Hlth Sci Brandenburg, Dept Immunol, Dessau, Germany
来源：
EXPERIMENTAL DERMATOLOGY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：28 / 29
页数：2
相关论文
共 50 条
  • [1] Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa
    Tzellos, Thrasivoulos
    van Straalen, Kelsey R.
    Kyrgidis, Athanassios
    Alavi, Afsaneh
    Goldfarb, Noah
    Gulliver, Wayne
    Jemec, Gregor B. E.
    Lowes, Michelle A.
    Marzano, Angelo Valerio
    Prens, Errol P.
    Sayed, Christopher J.
    van der Zee, Hessel H.
    Zouboulis, Christos C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (02) : 395 - 401
  • [2] PSYCHOMETRIC VALIDATION OF THE ELECTRONIC HIDRADENITIS SUPPURATIVA QUALITY OF LIFE (EHISQOL) QUESTIONNAIRE USING POOLED DATA FROM THE PHASE 3 BE HEARD TRIALS OF BIMEKIZUMAB IN HIDRADENITIS SUPPURATIVA
    Kirby, J.
    Ingram, J. R.
    Ciaravino, V
    Lambert, J.
    Rolleri, R.
    Pansar, I
    Mueller, E.
    Pelligra, C.
    VALUE IN HEALTH, 2023, 26 (06) : S289 - S289
  • [3] Comparison of the international hidradenitis suppurativa severity scoring system (IHS4) and hurley staging in hidradenitis suppurativa disease severity assessment: A post hoc analysis of the SUNSHINE and SUNRISE phase 3 trials
    Zouboulis, Christos C.
    Prens, Errol P.
    Sayed, Christopher
    Molina-Leyva, Alejandro
    Bettoli, Vincenzo
    Romanelli, Marco
    Szepietowski, Jacek C.
    Kasparek, Torben
    Lobach, Iryna
    Wozniak, Magdalena B.
    Ortmann, Christine-Elke
    Bachhuber, Teresa
    Muscianisi, Elisa
    Ravichandran, Shoba
    Tzellos, Thrasyvoulos
    EXPERIMENTAL DERMATOLOGY, 2023, 32 : 102 - 103
  • [4] Efficacy results using a novel hidradenitis suppurativa endpoint, HiSCR (hidradenitis suppurativa clinical response), from the placebo-controlled phase of a phase 2 adalimumab study
    Jemec, Gregor
    Sobell, Jeffrey
    Scheinfeld, Noah
    Sood, Sarika
    Gu, Yihua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB42 - AB42
  • [5] Efficacy Results Using a Novel Hidradenitis Suppurativa Endpoint, Hiscr (Hidradenitis Suppurativa Clinical Response), From The Placebo-Controlled Phase of a Phase 2 Adalimumab Study
    Scheinfeld, N. S.
    Sobell, J. M.
    Gu, Y.
    Sood, S.
    ANNALS OF EMERGENCY MEDICINE, 2013, 62 (04) : S151 - S151
  • [6] COMPARATIVE ANALYSIS OF HIDRADENITIS SUPPURATIVA QUALITY OF LIFE (HISQOL) AND DERMATOLOGY LIFE QUALITY INDEX (DLQI) SCORES USING DATA FROM PATIENTS WITH HIDRADENITIS SUPPURATIVA
    Vadhariya, A.
    Coak, E.
    Wallinger, H.
    Truman, I
    Teixiera, B.
    Garg, A.
    Kirby, J. S.
    VALUE IN HEALTH, 2022, 25 (07) : S582 - S582
  • [7] Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized study
    Kimball, Alexa B.
    Podda, Maurizio
    Alavi, Afsaneh
    Miller, Megan
    Shen, Yaung-Kaung
    Li, Shu
    Xu, Yan
    Han, Chenglong
    Fakharzadeh, Steven
    Yang, Ya-Wen
    DePrimo, Samuel
    Munoz, Ernesto
    Chen, Yanqing
    Passeron, Thierry
    Papp, Kim
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (10) : 2098 - 2108
  • [8] HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study
    Kimball, A. B.
    Sobell, J. M.
    Zouboulis, C. C.
    Gu, Y.
    Williams, D. A.
    Sundaram, M.
    Teixeira, H. D.
    Jemec, G. B. E.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (06) : 989 - 994
  • [9] PSYCHOMETRIC VALIDATION OF THE ELECTRONIC HIDRADENITIS SUPPURATIVA (HS) SYMPTOM DAILY DIARY (EHSSDD) AND ELECTRONIC HS SYMPTOM QUESTIONNAIRE (EHSSQ) USING DATA FROM THE PHASE 3 BE HEARD TRIALS OF BIMEKIZUMAB IN HS
    Ingram, J. R.
    Kirby, J.
    Ciaravino, V
    Rolleri, R.
    Pansar, I
    Lambert, J.
    Muller, E.
    Pelligra, C.
    VALUE IN HEALTH, 2023, 26 (06) : S280 - S280
  • [10] A Study on Seasonality and Regionality of Hidradenitis Suppurativa Using Real-Time Data from 2011 to 2021
    Lee, O. S.
    Sayed, C.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (10) : S161 - S161
12345